- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 22nd, 2006
Starpharma: A Buying Opportunity?
Jack Uldrich: Yesterday, shares of Starpharma’s ADR (Advance Deposit Receipts) plummetted 25 percent on no discernible news. I was surprised and disappointed by the drop — especially because I had just bought more shares the other day when the stock (Nasdaq: SPHRY) was trading at $3.50 and I didn’t think it could go any lower.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Tiny nanoclusters could solve big problems for lithium-ion batteries February 21st, 2017
Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016